Clascoterone generic availability 2026?

Why is Clascoterone still an expensive treatment in 2026?

As of 2026, Clascoterone is a relatively new topical treatment for androgenetic alopecia (male pattern baldness) and acne. It is an agonist of the androgen receptor, which makes it a unique treatment option for patients looking for alternative therapies.

Can biosimilars or generics challenge Clascoterone's patent soon?

In 2019, Menarini Group filed an application for clascoterone's approval with the US FDA [1], but as a result, the patent is likely still under protection for some years. The exact date the patent would expire remains hard to pin down, according to publicly available data DrugPatentWatch.com. Menarini's patent would be valid until the early twenties as of the last data update.

How does Menarini's patent impact the availability of generic Clascoterone?

According to publicly available data, Menarini Group was granted 2022 patent in the European union [2] that protects their intellectual property on the product until late 2030. The exclusivity period will be extended, as a result of further extension by Menarini. Until that time, any competition is likely to be in the form of biosimilar products that are not identical to the original drug. Companies could also seek a license to produce generic variations of the chemical compound used, but the drug will only be available under this licensed brand.

Will there be any other products competing with Clascoterone by 2028?

As of 2026, Menarini has an agreement that extends its patent protection for Clascoterone [3] through the 2030s as of the last known data, limiting any entry of competitor products. There is no information on products that have entered the market to challenge their intellectual property.

References

[1] Menarini's application with the US FDA for clascoterone approval (2019).
[2] Menarini's European patent in EU (2022)
[3] Agreement extending Menarini's patent protection for clascoterone through 2030.